Simvastatin increases plasma NO2− and NO3− levels in patients with hypercholesterolemia

In this study, plasma NO2− and NO3− (NOX−) levels were studied after lowering cholesterol with simvastatin in 26 outpatients with hypercholesterolemia (male, 9; female, 17; mean age, 59 ± 12 years; cholesterol level > 220 mg/dl). Simvastatin (5 mg) was orally administered once daily, and blood samples were collected before, and after 4 and 12 weeks of treatment. Total, very-low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) cholesterol were lowered (total, 254 ± 44 mg/dl to 209 ± 34 mg/dl; VLDL, 48 mg/dl [5–126 mg/dl] to 34 mg/dl [10–67 mg/dl]; LDL, 171 ± 41 mg/dl to 133 ± 37 mg/dl), but high-density lipoprotein (HDL) cholesterol was elevated (33 ± 9.5 mg/dl to 39 ± 11 mg/dl) at 12 weeks after starting simvastatin. Although the effects of simvastatin on the lipid levels nearly reached their maximum levels at 4 weeks, NOX− was elevated in a linear fashion with simvastatin (before; 8 ± 17 μmol/l, at 4 weeks; 44 ± 28 μmol/l, at 12 weeks; 57 ± 32 μmol/l). The % changes in the NOX− correlated directly with those in HDL-cholesterol at 12 weeks (P < 0.002) but not with other lipoprotein cholesterol fractions. These results suggest that simvastatin lowers cholesterol levels and elevates HDL wIn this study, plasma NO2− and NO3− (NOX−) levels were studied after lowering cholesterol with simvastatin in 26 outpatients with hypercholesterolemia (male, 9; female, 17; mean age, 59 ± 12 years; cholesterol level > 220 mg/dl). Simvastatin (5 mg) was orally administered once daily, and blood samples were collected before, and after 4 and 12 weeks of treatment. Total, very-low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) cholesterol were lowered (total, 254 ± 44 mg/dl to 209 ± 34 mg/dl; VLDL, 48 mg/dl [5–126 mg/dl] to 34 mg/dl [10–67 mg/dl]; LDL, 171 ± 41 mg/dl to 133 ± 37 mg/dl), but high-density lipoprotein (HDL) cholesterol was elevated (33 ± 9.5 mg/dl to 39 ± 11 mg/dl) at 12 weeks after starting simvastatin. Although the effects of simvastatin on the lipid levels nearly reached their maximum levels at 4 weeks, NOX− was elevated in a linear fashion with simvastatin (before; 8 ± 17 μmol/l, at 4 weeks; 44 ± 28 μmol/l, at 12 weeks; 57 ± 32 μmol/l). The % changes in the NOX− correlated directly with those in HDL-cholesterol at 12 weeks (P < 0.002) but not with other lipoprotein cholesterol fractions. These results suggest that simvastatin lowers cholesterol levels and elevates HDL while increasing the plasma NOX− levels.hile increasing the plasma NOX− levels.